Humana (NYSE:HUM – Get Rating) is set to issue its quarterly earnings data before the market opens on Wednesday, February 1st. Analysts expect the company to announce earnings of $1.46 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Humana (NYSE:HUM – Get Rating) last issued its earnings results on Wednesday, November 2nd. The insurance provider reported $6.88 EPS for the quarter, topping analysts’ consensus estimates of $6.25 by $0.63. Humana had a net margin of 3.07% and a return on equity of 19.99%. The company had revenue of $22.80 billion for the quarter, compared to the consensus estimate of $22.80 billion. On average, analysts expect Humana to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.
Humana Stock Performance
Humana stock opened at $500.35 on Wednesday. The firm has a 50 day simple moving average of $515.04 and a 200-day simple moving average of $505.41. The stock has a market cap of $63.34 billion, a price-to-earnings ratio of 22.69, a price-to-earnings-growth ratio of 1.26 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.35 and a quick ratio of 1.35. Humana has a 1-year low of $365.34 and a 1-year high of $571.30.
Humana Dividend Announcement
Analyst Ratings Changes
HUM has been the topic of several recent analyst reports. Mizuho upped their price target on Humana from $529.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, November 10th. Cowen increased their target price on shares of Humana from $547.00 to $647.00 in a research note on Monday, November 7th. JPMorgan Chase & Co. decreased their price objective on shares of Humana from $630.00 to $625.00 and set an “overweight” rating on the stock in a report on Friday, January 6th. Wells Fargo & Company lifted their target price on shares of Humana from $558.00 to $610.00 in a report on Tuesday, November 8th. Finally, Morgan Stanley upped their price target on Humana from $549.00 to $620.00 and gave the stock an “overweight” rating in a research note on Monday, October 31st. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humana has a consensus rating of “Moderate Buy” and an average target price of $602.50.
Insider Buying and Selling at Humana
In other news, CAO William Kevin Fleming sold 11,157 shares of the business’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $565.61, for a total transaction of $6,310,510.77. Following the completion of the transaction, the chief accounting officer now directly owns 2,542 shares of the company’s stock, valued at $1,437,780.62. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Humana news, Director David A. Jr/Ky Jones sold 15,000 shares of the firm’s stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $501.72, for a total value of $7,525,800.00. Following the sale, the director now directly owns 42,028 shares in the company, valued at $21,086,288.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO William Kevin Fleming sold 11,157 shares of Humana stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $565.61, for a total value of $6,310,510.77. Following the sale, the chief accounting officer now directly owns 2,542 shares of the company’s stock, valued at $1,437,780.62. The disclosure for this sale can be found here. Insiders have sold 51,570 shares of company stock valued at $27,938,777 in the last quarter. Corporate insiders own 0.39% of the company’s stock.
Institutional Investors Weigh In On Humana
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers increased its stake in Humana by 0.5% in the first quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock valued at $2,135,000 after purchasing an additional 26 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Humana by 0.6% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 4,962 shares of the insurance provider’s stock valued at $2,407,000 after buying an additional 32 shares during the last quarter. Blair William & Co. IL raised its stake in Humana by 0.6% during the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after acquiring an additional 32 shares in the last quarter. Orion Portfolio Solutions LLC lifted its position in Humana by 5.8% in the first quarter. Orion Portfolio Solutions LLC now owns 715 shares of the insurance provider’s stock valued at $311,000 after acquiring an additional 39 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Humana by 33.6% in the first quarter. Covestor Ltd now owns 171 shares of the insurance provider’s stock valued at $75,000 after acquiring an additional 43 shares in the last quarter. Institutional investors and hedge funds own 93.38% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.